Revance News: Crown's Acquisition Reshapes Aesthetics Market
Crown Laboratories' acquisition of Revance Therapeutics for $924 million ($6.66 per share) marks a significant reshaping of the aesthetics market. This 89% premium over Revance's closing price signals a bold move by Crown, combining its established skincare distribution network with Revance's innovative injectable technologies, including the long-lasting botulinum toxin, Daxxify, and RHA fillers. The deal, expected to close by the end of the year, presents both considerable opportunities and potential challenges....